全文获取类型
收费全文 | 1825篇 |
免费 | 215篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 43篇 |
妇产科学 | 48篇 |
基础医学 | 360篇 |
口腔科学 | 73篇 |
临床医学 | 213篇 |
内科学 | 464篇 |
皮肤病学 | 23篇 |
神经病学 | 88篇 |
特种医学 | 89篇 |
外科学 | 254篇 |
综合类 | 17篇 |
预防医学 | 120篇 |
眼科学 | 7篇 |
药学 | 142篇 |
中国医学 | 1篇 |
肿瘤学 | 67篇 |
出版年
2021年 | 29篇 |
2020年 | 23篇 |
2019年 | 23篇 |
2018年 | 30篇 |
2017年 | 22篇 |
2016年 | 34篇 |
2015年 | 36篇 |
2014年 | 51篇 |
2013年 | 60篇 |
2012年 | 89篇 |
2011年 | 77篇 |
2010年 | 58篇 |
2009年 | 39篇 |
2008年 | 71篇 |
2007年 | 94篇 |
2006年 | 71篇 |
2005年 | 72篇 |
2004年 | 57篇 |
2003年 | 49篇 |
2002年 | 59篇 |
2001年 | 46篇 |
2000年 | 60篇 |
1999年 | 43篇 |
1998年 | 23篇 |
1997年 | 25篇 |
1996年 | 31篇 |
1995年 | 34篇 |
1994年 | 31篇 |
1993年 | 24篇 |
1992年 | 24篇 |
1991年 | 27篇 |
1990年 | 21篇 |
1989年 | 28篇 |
1988年 | 32篇 |
1987年 | 19篇 |
1986年 | 25篇 |
1985年 | 25篇 |
1984年 | 26篇 |
1983年 | 23篇 |
1977年 | 33篇 |
1976年 | 18篇 |
1975年 | 19篇 |
1974年 | 58篇 |
1973年 | 44篇 |
1972年 | 44篇 |
1971年 | 30篇 |
1970年 | 25篇 |
1969年 | 16篇 |
1968年 | 20篇 |
1967年 | 18篇 |
排序方式: 共有2041条查询结果,搜索用时 31 毫秒
41.
Paul Rohde Charles W. Turner Holly B. Waldron Janet L. Brody Jenel Jorgensen 《Journal of clinical child and adolescent psychology》2018,47(4):595-607
Using data from a randomized trial in which adolescents with depressive and substance use disorders (SUD) received treatments for both disorders in either a sequenced or coordinated manner, we (a) determine the number and nature of depression response profiles through 1-year posttreatment and (b) examine whether 8 previously identified factors predict profile membership. There were 170 adolescents (M age = 16.4 years; 22% female; 28% Hispanic, 61% Non-Hispanic White) with comorbid depressive disorder/SUD randomized to one of three sequences of receiving the Adolescent Coping With Depression Course and Functional Family Therapy for SUD (depression treatment followed by SUD treatment; SUD treatment followed by depression treatment; coordinated treatment). Depression was assessed at 7 points from baseline to 1-year follow-up. A 4-class solution fit the data best, with groups labeled Mildly Depressed Responders (57.1%), Depressed Responders (18.8%), Depressed Non-Responders (12.9%), and Depressed with Recurrence (11.2%). The 4 change profiles differed on indices of all but 1 predictor (age); most differences were driven by lower scores among Mildly Depressed Responders. Profile membership was most strongly predicted by depression severity, cognitive distortions, hopelessness, and global functioning. The strongest predictor of Nonresponse was low family cohesion, whereas Recurrence was associated with hopelessness, suicide attempts, and starting treatment near the end of the school year. Most depressed adolescents experienced a positive response that was maintained. Understanding the most common profiles of depression change during and following treatment and the variables that predict change can help improve treatment outcomes and advance tailoring efforts. 相似文献
42.
43.
Ming-Cheng Luo Yong Q. Gu Frank M. You Karin R. Deal Yaqin Ma Yuqin Hu Naxin Huo Yi Wang Jirui Wang Shiyong Chen Chad M. Jorgensen Yong Zhang Patrick E. McGuire Shiran Pasternak Joshua C. Stein Doreen Ware Melissa Kramer W. Richard McCombie Shahryar F. Kianian Mihaela M. Martis Klaus F. X. Mayer Sunish K. Sehgal Wanlong Li Bikram S. Gill Michael W. Bevan Hana ?imková Jaroslav Dole?el Song Weining Gerard R. Lazo Olin D. Anderson Jan Dvorak 《Proceedings of the National Academy of Sciences of the United States of America》2013,110(19):7940-7945
44.
45.
46.
CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis 总被引:1,自引:0,他引:1
Mason U Aldrich J Breedveld F Davis CB Elliott M Jackson M Jorgensen C Keystone E Levy R Tesser J Totoritis M Truneh A Weisman M Wiesenhutter C Yocum D Zhu J 《The Journal of rheumatology》2002,29(2):220-229
OBJECTIVE: Double blind studies were conducted with the anti-CD4 monoclonal antibody (Mab) keliximab in patients with active, stable rheumatoid arthritis (RA), to confirm preliminary evidence of efficacy and safety from open. uncontrolled studies. METHODS: We enrolled 136 and 186 patients into 2 consecutive, randomized, double blind trials, with similar populations [apart from inclusion of disease modifying antirheumatic drug (DMARD)-na?ve patients in Study 2]. Patients received 4 weeks intravenous placebo or keliximab [40, 80, 120, or 140 mg twice weekly (bw), or 240 mg once weekly (ow)].The primary endpoint was the American College of Rheumatology (ACR) 20 response criteria, one week after the end of treatment. RESULTS: ACR 20 response rates in Study I were 19%, 42%, 51%*, and 69%* (*p < 0.05 compared to placebo), with placebo, 40, 80, or 140 mg keliximab bw, respectively. The response rates in Study 2 were 30%, 39%, 46% and 47% with placebo, 80 or 120 mg bw, or 240 mg keliximab ow, respectively. In the 2 studies, there was a dose dependent increase in peripheral blood CD4+ T cell coating with keliximab, but a different pattern of CD4 depletion was seen. While only 12% of keliximab treated patients in Study I had CD4 counts below 250 cells/mm3 at the end of the treatment period, 47% fell below this level in Study 2. Clinical response was not correlated with CD4 depletion, but was correlated with CD4+ T cell coating with keliximab. CONCLUSION: Coating of peripheral blood CD4+ T cells with keliximab, but not CD4 depletion, is a determinant of clinical response. 相似文献
47.
Anti-tumor necrosis factor-a (anti-TNF-a) therapy strategies result in significant clinical benefits in patients with rheumatoid arthritis, but with an increased rate of serious infectious diseases. We describe a patient receiving infliximab who developed a primary cutaneous Nocardia otitidiscaviarum infection after a skin injury. 相似文献
48.
Sarah Jorgensen Mira Zurayk Samantha Yeung Jill Terry Maureen Dunn Paul Nieberg Annie Wong-Beringer 《The American journal of emergency medicine》2018,36(1):12-17
Background
Optimal management of urinary tract infections (UTIs) in the emergency department (ED) is challenging due to high patient turnover, decreased continuity of care, and treatment decisions made in the absence of microbiologic data. We sought to identify risk factors for return visits in ED patients treated for UTI.Methods
A random sample of 350 adult ED patients with UTI by ICD 9/10 codes was selected for review. Relevant data was extracted from medical charts and compared between patients with and without ED return visits within 30 days (ERVs).Results
We identified 51 patients (15%) with 59 ERVs, of whom 6% returned within 72 h. Nearly half of ERVs (47%) were UTI-related and 33% of ERV patients required hospitalization. ERVs were significantly more likely (P < 0.05) in patients with the following: age ≥ 65 years; pregnancy; skilled nursing facility residence; dementia; psychiatric disorder; obstructive uropathy; healthcare exposure; temperature ≥ 38 °C heart rate > 100; and bacteremia. Escherichia coli was the most common uropathogen (70%) and susceptibility rates to most oral antibiotics were below 80% in both groups except nitrofurantoin (99% susceptible).Cephalexin was the most frequently prescribed antibiotic (51% vs. 44%; P = 0.32). Cephalexin bug-drug mismatches were more common in ERV patients (41% vs. 15%; P = 0.02). Culture follow-up occurred less frequently in ERV patients (75% vs. 100%; P < 0.05).Conclusions
ERV in UTI patients may be minimized by using ED-source specific antibiogram data to guide empiric treatment decisions and by targeting at-risk patients for post-discharge follow-up. 相似文献49.
50.